Logo image of UPB

UPSTREAM BIO INC (UPB) Stock Fundamental Analysis

NASDAQ:UPB - Nasdaq - US91678A1079 - Currency: USD

10.39  -0.38 (-3.53%)

After market: 10.39 0 (0%)

Fundamental Rating

3

UPB gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for UPB as it has an excellent financial health rating, but there are worries on the profitability. UPB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year UPB has reported negative net income.
UPB Yearly Net Income VS EBIT VS OCF VS FCFUPB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 -10M -20M -30M -40M

1.2 Ratios

UPB's Return On Assets of -16.44% is amongst the best of the industry. UPB outperforms 81.06% of its industry peers.
Looking at the Return On Equity, with a value of -17.34%, UPB belongs to the top of the industry, outperforming 87.43% of the companies in the same industry.
Industry RankSector Rank
ROA -16.44%
ROE -17.34%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
UPB Yearly ROA, ROE, ROICUPB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 -100 -200 -300

1.3 Margins

UPB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UPB Yearly Profit, Operating, Gross MarginsUPB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 -500 -1K -1.5K

More info and screens

9

2. Health

2.1 Basic Checks

UPB does not have a ROIC to compare to the WACC, probably because it is not profitable.
UPB has about the same amout of shares outstanding than it did 1 year ago.
There is no outstanding debt for UPB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
UPB Yearly Shares OutstandingUPB Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 10M 20M 30M 40M 50M
UPB Yearly Total Debt VS Total AssetsUPB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

UPB has an Altman-Z score of 27.07. This indicates that UPB is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of UPB (27.07) is better than 94.87% of its industry peers.
UPB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 27.07
ROIC/WACCN/A
WACC10.86%
UPB Yearly LT Debt VS Equity VS FCFUPB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 20.90 indicates that UPB has no problem at all paying its short term obligations.
UPB has a better Current ratio (20.90) than 95.04% of its industry peers.
A Quick Ratio of 20.90 indicates that UPB has no problem at all paying its short term obligations.
UPB's Quick ratio of 20.90 is amongst the best of the industry. UPB outperforms 95.04% of its industry peers.
Industry RankSector Rank
Current Ratio 20.9
Quick Ratio 20.9
UPB Yearly Current Assets VS Current LiabilitesUPB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for UPB have decreased strongly by -60.28% in the last year.
The Revenue has grown by 96.37% in the past year. This is a very strong growth!
EPS 1Y (TTM)-60.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)96.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -37.93% on average over the next years. This is quite bad
UPB is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -7.60% yearly.
EPS Next Y-987.79%
EPS Next 2Y-79.33%
EPS Next 3Y-55.38%
EPS Next 5Y-37.93%
Revenue Next Year-6.51%
Revenue Next 2Y-14.45%
Revenue Next 3Y-10.66%
Revenue Next 5Y-7.6%

3.3 Evolution

UPB Yearly Revenue VS EstimatesUPB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 500K 1M 1.5M 2M
UPB Yearly EPS VS EstimatesUPB Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

UPB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year UPB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UPB Price Earnings VS Forward Price EarningsUPB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UPB Per share dataUPB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A cheap valuation may be justified as UPB's earnings are expected to decrease with -55.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-79.33%
EPS Next 3Y-55.38%

More info and screens

0

5. Dividend

5.1 Amount

UPB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UPSTREAM BIO INC

NASDAQ:UPB (1/24/2025, 8:12:55 PM)

After market: 10.39 0 (0%)

10.39

-0.38 (-3.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change100%
Market Cap556.90M
Analysts82.5
Price Target57.63 (454.67%)
Short Float %6.13%
Short Ratio6.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 233.99
P/FCF N/A
P/OCF N/A
P/B 2.52
P/tB 2.52
EV/EBITDA N/A
EPS(TTM)-0.75
EYN/A
EPS(NY)-2.4
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.04
BVpS4.11
TBVpS4.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.44%
ROE -17.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20.9
Quick Ratio 20.9
Altman-Z 27.07
F-ScoreN/A
WACC10.86%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-60.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-987.79%
EPS Next 2Y-79.33%
EPS Next 3Y-55.38%
EPS Next 5Y-37.93%
Revenue 1Y (TTM)96.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-6.51%
Revenue Next 2Y-14.45%
Revenue Next 3Y-10.66%
Revenue Next 5Y-7.6%
EBIT growth 1Y-67.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-91.35%
EBIT Next 3Y-59.45%
EBIT Next 5YN/A
FCF growth 1Y-99.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-99.39%
OCF growth 3YN/A
OCF growth 5YN/A